AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02091661 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical retropubic prostatectomy
Description: The surgery arm underwent radical retropubic prostatectomy, performed by a technique described by Walsh. The prostatectomy is performed in retrograde way, preserving the neurovascular bundles if feasible. The degree to which the surgeon preserve the nerves is categorized as non-nerve-sparing, unilateral nerve-sparing, or bilateral nerve-sparing. Pelvic lymph node dissection is performed if feasible. The operative time is about 2 to 3 hours and required hospital stay. The patient has a urinary catheter placed for 6 to 9 days to facilitate bladder emptying.
Study NCT02091661 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam radiotherapy
Description: External beam radiotherapy is carried out with intensity-modulated radiation technique. The treatment is designed to maximize the radiation dose to the prostate and seminal vesicles and minimize exposure to surrounding structures, including the bladder and rectum. Radiation to the prostate was delivered in fractionated doses divided over multiple treatments (180 to 200 centigray (cGy) daily fractions, 5 days per week) for a total dose to the prostate of 68 to 77 gray (Gy), prescribed at 90% to 100% of the isodose line.
Study NCT00501826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00501826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT00501826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO
Study NCT00501826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT00501826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO
Study NCT00501826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV and PO
Study NCT00501826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelarabine
Description: Given IV
Study NCT00501826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV
Study NCT00501826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT00501826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT00501826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT01118325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: Drug oral treatment
Study NCT01118325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Drug oral treatment
Study NCT03532646 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: upper endoscopy
Description: endoscopy of the gastrointestinal tract
Study NCT03383549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation
Description: Each subject undergoes a combined rehabilitation protocol, which will be administered on a daily basis, designed to alternate physical exercises and cognitive training. Each daily session lasts between 30 and 45 minutes. The complete protocol lasts 8 weeks.
Study NCT03421483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid supplementation
Description: Participants receive a 400 microgram Folic Acid supplement
Study NCT03421483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Adult Multivitamin
Description: Participants will receive an adult multivitamin supplement
Study NCT01611753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: packed red blood cell transfusion
Description: Patients wil be randomized en two groups, in the liberal group they must received transfusions immediately, as the objective was to maintain hemoglobin levels above 9.0 g/dL. In the restrictive group they will receive transfusion to maintain hemoglobin levels above 7.0g/dL
Study NCT03421483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Adult Multivitamin
Description: Participants will receive an adult multivitamin supplement
Study NCT00738933 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary plant stanols
Description: Daily 2 grams of plant stanols in a margarine preparation for 4-8 weeks before the operation
Study NCT00738933 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary plant sterols
Description: Daily 2 grams of plant sterols in a margarine preparation for 4-8 weeks before the operation
Study NCT00738933 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Margarine product without plant stanol or sterol esters
Study NCT04279717 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: No interventions planned: treatment of patients at the discretion of the treating/responsible physician
Study NCT02766023 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus crispatus CTV-05
Description: LACTIN-V is an intravaginal live biotherapeutic product composed of Lactobacillus crispatus CTV-05 (LACTIN-V, Osel Inc) in a vaginal applicator. Subjects receive 2x10\^9 cfu/dose applied vaginally daily x 5 days then twice weekly x 10 weeks.
Study NCT02766023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole is a nitroimidazole. Metronidazole gel (MetroGel) is applied vaginally 7.5 mg/gm daily for 5 days
Study NCT02766023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole is a nitroimidazole. Metronidazole gel (MetroGel) is applied vaginally 7.5 mg/gm daily for 5 days
Study NCT00528567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was administered at a dose equivalent of 5 mg/kg/week using 1 of 3 different scheduling options depending on the schedule of the adjuvant chemotherapy regimen selected for an individual patient.
Study NCT00528567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard adjuvant chemotherapy
Description: All chemotherapy schedules and doses for each patient were prescribed according to the labeled indication of the country in which the patient was receiving therapy.
Study NCT00528567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard adjuvant chemotherapy
Description: All chemotherapy schedules and doses for each patient were prescribed according to the labeled indication of the country in which the patient was receiving therapy.
Study NCT01410435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monofer
Description: Infusion according to current HB level
Study NCT03455192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synbiotic Supplement
Study NCT03455192 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study NCT01839162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary angiography
Description: Diagnostic coronary angiography
Study NCT01839162 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Coronary angiography
Description: Diagnostic coronary angiography
Study NCT01839162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: Percutaneous coronary intervention
Study NCT01839162 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: PCI
Description: Percutaneous coronary intervention
Study NCT01839162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right approach
Description: Right transradial access
Study NCT01839162 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Right approach
Description: Right transradial access
Study NCT01839162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left approach
Description: Left transradial access
Study NCT01839162 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Left approach
Description: Left transradial access
Study NCT01132066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS will lead to an increase in cortical excitability
Study NCT01132066 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: Sham will provide identical subjective sensation as tDCS
Study NCT01513525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Single dose of 0.60 mg administered subcutaneously in three different injection sites on three separate dosing visits
Study NCT01012154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endomicroscope
Description: Endomicroscopic images and biopsies are taken at several positions on the tumor.
Study NCT03601936 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Evivo Infant Gut Bifidobacterium Screening Test
Description: Operators at each test site will collect and test infant stool specimens according to the Evivo Infant Gut Bifidobacterium Screening Test protocol.
Study NCT01803477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: once daily for two consecutive days (Picato)
Study NCT01803477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: once daily for two consecutive days (Picato)
Study NCT00695851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCK3145
Description: i.v. bolus either 15 mg/m2 weekly of PCK3145.
Study NCT00695851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCK3145
Description: by i.v. bolus 7.5 mg/m2 twice per week of PCK3145
Study NCT00665743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN400
Description: naproxen 500 mg /esomeprazole 20 mg
Study NCT00665743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen
Description: naproxen 500 mg tablet
Study NCT00665743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen
Description: naproxen 500 mg
Study NCT03422289 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: myo-inositol plus folic acid
Description: this treatment is made in the first phase of the study for three months
Study NCT03422289 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: myo-inositol plus folic acid plus alpha-lactalbumin
Description: this treatment is made in the second phase of the study and it has a new molecule added to the previous ones administered in the first phase of the study
Study NCT00490633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ear Loop Procedure Mask
Description: Facemasks were requested to be worn while participants were in the residence hall for year one, and while they were in residence halls for a minimum of six hours per day in year two.
Study NCT00490633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 62% Ethyl Alcohol Hand Sanitizer
Description: Hand sanitizer was provided to participants in the facemask and hand hygiene arm for year one and year two of the study.
Study NCT04281589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: if the ventilation parameter caused desaturation or hypercapnia we will change the parameter
Description: we will increased fi02
Study NCT02556866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Prednisone treatment plus rituximab administered by slow intravenous infusion at 375 mg/m2 at D1, D8, D15 and D22.
Study NCT02556866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Study NCT02556866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT02556866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00201838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: The starting dose will be 1000mg/m2 IV, weekly x 7 with a one week rest followed by weekly x 3 with one week rest for the remainder of treatment.
Study NCT00201838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: The starting dose will be 1000mg/m2 IV, weekly x 7 with a one week rest followed by weekly x 3 with one week rest for the remainder of treatment.
Study NCT00201838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept will be self administered subcutaneously by patients with injections 11 prepared by the investigational pharmacy, beginning 7 days prior to the first dose of gemcitabine and continued twice weekly for the duration of the study.
Study NCT03654014 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SofPulse
Description: SofPulse PEMF device treatment of the brain after traumatic injury
Study NCT03654014 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SofPulse
Description: SofPulse PEMF device treatment of the brain after traumatic injury
Study NCT03654014 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SofPulse
Description: SofPulse PEMF device treatment of the brain after traumatic injury
Study NCT02172287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium (Ba679 BR)
Description: One capsule once daily by oral inhalation
Study NCT02172287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Inhalation aerosol twice daily
Study NCT02172287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Tiotropium )
Description: Placebo for Tiotropium delivered by inhalation capsule
Study NCT02172287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Tiotropium )
Description: Placebo for Tiotropium delivered by inhalation capsule
Study NCT02172287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Salmeterol)
Description: Placebo for Salmeterol delivered by inhalation aerosol
Study NCT02172287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Salmeterol)
Description: Placebo for Salmeterol delivered by inhalation aerosol
Study NCT02613689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scheduled Gradual Reduction (SGR)
Description: Participants in this group will group will receive the Scheduled Gradual Reduction (SGR) smokeless tobacco cessation reduction intervention via text message over a period of four weeks. Participants will initially report their smokeless tobacco use according to their usual habit, and over the course of the intervention be directed via text message precise times to start and stop each instance of smokeless tobacco use, gradually reducing the occurrences of use. In addition, this group will also receive the support messages that are sent to the control group.
Study NCT02613689 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Messages
Description: Participants in this group will receive text messages about smokeless tobacco cessation in the form of counseling messages at various times throughout the day over a period of four weeks.
Study NCT02613689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messages
Description: Participants in this group will receive text messages about smokeless tobacco cessation in the form of counseling messages at various times throughout the day over a period of four weeks.
Study NCT03496324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nurofen for Children®
Description: Nurofen for Children® 400 mg/10 ml
Study NCT03496324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Algifor® Junior
Description: Algifor® Junior 400 mg/20 ml
Study NCT02514408 — intervention group
Intervention type: PROCEDURE
Intervention: Catheter Management
Description: Insertion of venous catheter under ultrasound guidance
Study NCT02514408 — intervention group
Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Collection of blood samples
Study NCT02514408 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01145495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01145495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT01145495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT00024167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 intravenous piggyback (IVPB) over 1 hour, Day 1, every 3 weeks.
Study NCT00024167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride
Description: 20 mg/m2 IV, day 1 on Weeks 1, 3, 5
Study NCT00024167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estramustine phosphate sodium
Description: 140 mg orally 3 x day, Days 1 through 7 on Weeks 2, 4, 6
Study NCT00024167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: 400 mg orally (po) 3 x day, Days 1 through 7
Study NCT00024167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg orally 2 x daily, weeks 1-14
Study NCT00024167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: 4 mg/m2 IVPB, Day 1 on Weeks 2, 4, 6
Study NCT00024167 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Strontium chloride Sr 89
Description: One dose (4 mCi total dose) IV
Study NCT00024167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4 mg is given orally at 12 and 1 hours before and 12 hours after docetaxel.
Study NCT04597957 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Rx Intervention group
Description: Fresh Rx Intervention participants will be able to fill their prescription at the FQHC based Farmers Market for fresh produce up to eight times during the 15-week Fresh Rx program. The provided debit cards will be loaded with the $10 stipend at each visit. At each market session, cooking demonstrations will take place that reinforce healthy food options and how to prepare foods that were available at the Mercado.~All control group participants will be given flyers describing all the health and wellness programs at the FQHC including the Mercado. Control group participants will receive a $10 gift card to a national brand pharmacy (no fresh produce available). The enrollment time for the control group will overlap with the Fresh Rx group. After a 3-month time period, the control group will follow up and be given a $20 gift card to the same national brand pharmacy.
Study NCT04597957 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fresh Rx Intervention group
Description: Fresh Rx Intervention participants will be able to fill their prescription at the FQHC based Farmers Market for fresh produce up to eight times during the 15-week Fresh Rx program. The provided debit cards will be loaded with the $10 stipend at each visit. At each market session, cooking demonstrations will take place that reinforce healthy food options and how to prepare foods that were available at the Mercado.~All control group participants will be given flyers describing all the health and wellness programs at the FQHC including the Mercado. Control group participants will receive a $10 gift card to a national brand pharmacy (no fresh produce available). The enrollment time for the control group will overlap with the Fresh Rx group. After a 3-month time period, the control group will follow up and be given a $20 gift card to the same national brand pharmacy.
Study NCT00850850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: physostigmine
Description: 1 mg of physostigmine time 0 min. If the condition persisted after 15 min. the same amount of active drug would be administered once again.
Study NCT00850850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic sodium chloride solution
Description: Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 ml of isotonic sodium chloride solution (placebo) time 0 min. If the condition persisted after 15 min. the same amount of non-active drug would be administered once again.
Study NCT03262792 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose
Study NCT03262792 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Andrographis Paniculata
Description: Andrographis Paniculata 150 mg
Study NCT03262792 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Andrographis Paniculata
Description: Andrographis Paniculata 300 mg
Study NCT03122496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.
Study NCT03122496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.
Study NCT03122496 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: SBRT at 9Gy x 3 per standard of care given within 2 weeks after the completion of Cycle 1 of durvalumab (MEDI4736) and tremelimumab